Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15189122 | 0.85 | KMT2A (0.61) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL1883814 | 0.84 | KMT2A (0.60) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL1567888 | 0.77 | EPHX2 (0.47) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL12639506 | 0.76 | LMNA (0.47) | MEN1KMT2ANPSR1GAAMAPT | |
| SCHEMBL12639608 | 0.76 | EPHX2 (0.46) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL9849508 | 0.76 | SMYD3 (0.75) | MEN1KMT2ANPSR1HTTMAPT | |
| SCHEMBL12639573 | 0.75 | EPHX2 (0.45) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL12639550 | 0.75 | GAA (0.44) | MEN1KMT2ANPSR1GAAHTT | |
| SCHEMBL12639520 | 0.75 | EPHX2 (0.44) | EPHX2 | |
| SCHEMBL12639509 | 0.75 | KMT2A (0.45) | MEN1KMT2ANPSR1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-8519188-B2 | Compounds which can be used for the treatment of cancers | Marc-Henry Pitty (FR) | 2013-08-27 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | CYTOMICS SYSTEMS (FR) | 2011-05-05 | — | — | US | disclosed |
| WO-2009150248-A1 | COMPOUNDS WHICH CAN BE USED FOR THE TREATMENT OF CANCERS | CYTOMICS SYSTEMS (FR) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104162-A1 | Compounds which can be used for the Treatment of Cancers | VHL, CYP11B2, SLC10A1 | MEN1 70/4885KMT2A 3789/4885NPSR1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.